Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein

Background Loss‐of‐function mutations in the ATP‐binding cassette (ABCA)‐1 gene locus are the underlying cause for familial hypoalphalipoproteinemia, providing a human isolated low‐HDL model. In these familial hypoalphalipoproteinemia subjects, we evaluated the impact of isolated low HDL on endothelial function and the vascular effects of an acute increase in HDL. Methods and Results In 9 ABCA1 heterozygotes and 9 control subjects, vascular function was assessed by venous occlusion plethysmography. Forearm blood flow responses to the endothelium‐dependent and ‐independent vasodilators serotonin (5HT) and sodium nitroprusside, respectively, and the inhibitor of nitric oxide synthase NG‐monomethyl‐Larginine (L‐NMMA) were measured. Dose‐response curves were repeated after systemic infusion of apolipoprotein A‐I/phosphatidylcholine (apoA‐I/PC) disks. At baseline, ABCA1 heterozygotes had decreased HDL levels (0.4±0.2 mmol/L; P<0.05), and their forearm blood flow responses to both 5HT (maximum, 49.0±10.4%) and L‐NMMA (maximum, ‐22.8±22.9%) were blunted compared with control subjects (both P≤0.005). Infusion of apoA‐I/PC disks increased plasma HDL to 1.3±0.4 mmol/L in ABCA1 heterozygotes, which resulted in complete restoration of vasomotor responses to both 5HT and L‐NMMA (both P≤0.001). Endothelium‐independent vasodilation remained unaltered throughout the protocol. Conclusions In ABCA1 heterozygotes, isolated low HDL is associated with endothelial dysfunction, attested to by impaired basal and stimulated NO bioactivity. Strikingly, both parameters were completely restored after a single, rapid infusion of apoA‐I/PC. These findings indicate that in addition to its long‐term role within reverse cholesterol transport, HDL per se also exerts direct beneficial effects on the arterial wall. (Circulation. 2003;107:2944‐2948.)

[1]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[2]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[3]  J. E. Doran,et al.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia , 1996, The Journal of experimental medicine.

[4]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[5]  E. Schiffrin,et al.  Correlation of endothelial function in large and small arteries in human essential hypertension. , 2001, Journal of hypertension.

[6]  A. Quyyumi,et al.  Prognostic Value of Coronary Vascular Endothelial Dysfunction , 2002, Circulation.

[7]  Deventer,et al.  Distribution and Kinetics of Lipoprotein-Bound Endotoxin , 2001, Infection and Immunity.

[8]  M. Freeman,et al.  Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. , 2000, Journal of lipid research.

[9]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.

[10]  T. Rabelink,et al.  Folic acid reverts dysfunction of endothelial nitric oxide synthase. , 2000, Circulation research.

[11]  I. Yuhanna,et al.  High Density Lipoprotein Prevents Oxidized Low Density Lipoprotein-induced Inhibition of Endothelial Nitric-oxide Synthase Localization and Activation in Caveolae* , 2000, The Journal of Biological Chemistry.

[12]  G. Anantharamaiah,et al.  A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. , 2001, Journal of lipid research.

[13]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[14]  T. Rabelink,et al.  Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication , 1995, The Lancet.

[15]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[16]  F. Werf,et al.  Malondialdehyde-modified LDL as a marker of acute coronary syndromes. , 1999, JAMA.

[17]  M. Hayden,et al.  Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. , 2000, The Journal of clinical investigation.

[18]  T. Rabelink,et al.  Cellular regulation of endothelial nitric oxide synthase. , 2001, American journal of physiology. Renal physiology.

[19]  D. Sviridov,et al.  Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). , 2001, The Biochemical journal.

[20]  G. Fonarow,et al.  formation of , 2022 .

[21]  M. Nikolova-Karakashian,et al.  High Density Lipoprotein Binding to Scavenger Receptor, Class B, Type I Activates Endothelial Nitric-oxide Synthase in a Ceramide-dependent Manner* , 2002, The Journal of Biological Chemistry.

[22]  G. Dagenais,et al.  Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) , 1995, The American journal of cardiology.

[23]  P. Lerch,et al.  Production and Characterization ofa Reconstituted High Density Lipoprotein for Therapeutic Applications , 1996, Vox sanguinis.

[24]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[25]  A. Zwinderman,et al.  Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study , 2002, The Lancet.

[26]  F. Semeria,et al.  Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. , 2001, Journal of lipid research.

[27]  T. Langmann,et al.  Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice , 2000, Nature Genetics.

[28]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[29]  R. Kirchmair,et al.  Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[30]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[31]  J. Deanfield,et al.  Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. , 1997, Circulation.

[32]  M. Watkins,et al.  Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.

[33]  D. Maron The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. , 2000, The American journal of cardiology.

[34]  C. Fielding,et al.  A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. , 2000, Biochemistry.

[35]  T. Langmann,et al.  Native LDL Upregulation of ATP‐Binding Cassette Transporter‐1 in Human Vascular Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.